WO2007093657A3 - Método para el diagnóstico molecular de cáncer de próstata y kit para implementar el método - Google Patents

Método para el diagnóstico molecular de cáncer de próstata y kit para implementar el método Download PDF

Info

Publication number
WO2007093657A3
WO2007093657A3 PCT/ES2007/000085 ES2007000085W WO2007093657A3 WO 2007093657 A3 WO2007093657 A3 WO 2007093657A3 ES 2007000085 W ES2007000085 W ES 2007000085W WO 2007093657 A3 WO2007093657 A3 WO 2007093657A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostate cancer
kit
molecular diagnosis
implementing same
prostate
Prior art date
Application number
PCT/ES2007/000085
Other languages
English (en)
French (fr)
Other versions
WO2007093657A2 (es
Inventor
Okatsu Timothy Thomson
Gascon Raquel Bermudo
Ortiz Angel Ramirez
David Abia
Alonso Carlos Matinez
Ruiz Luis Pedro Fernandez
Fabrega Berta Ferrer
Gueerri Elias Campo
Vives Elisabet Rosell
Original Assignee
Oryzon Genomics Sa
Fundacio Privada Clinic Per A
Consejo Superior Investigacion
Okatsu Timothy Thomson
Gascon Raquel Bermudo
Ortiz Angel Ramirez
David Abia
Alonso Carlos Matinez
Ruiz Luis Pedro Fernandez
Fabrega Berta Ferrer
Gueerri Elias Campo
Vives Elisabet Rosell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics Sa, Fundacio Privada Clinic Per A, Consejo Superior Investigacion, Okatsu Timothy Thomson, Gascon Raquel Bermudo, Ortiz Angel Ramirez, David Abia, Alonso Carlos Matinez, Ruiz Luis Pedro Fernandez, Fabrega Berta Ferrer, Gueerri Elias Campo, Vives Elisabet Rosell filed Critical Oryzon Genomics Sa
Priority to US12/224,061 priority Critical patent/US20100227317A1/en
Priority to EP07730326A priority patent/EP2000543A4/en
Publication of WO2007093657A2 publication Critical patent/WO2007093657A2/es
Publication of WO2007093657A3 publication Critical patent/WO2007093657A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un método para el diagnóstico molecular de cáncer de próstata que comprende el análisis in vitro de la sobreexpresión o infraexpresión de combinaciones de genes capaces de discriminar con alta significación estadística las muestras de próstata tumoral de las muestras de próstata no tumoral. La presente invención se refiere también a un kit para el diagnóstico molecular del cáncer de próstata capaz de llevar a cabo la detección mencionada anteriormente.
PCT/ES2007/000085 2006-02-15 2007-02-15 Método para el diagnóstico molecular de cáncer de próstata y kit para implementar el método WO2007093657A2 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/224,061 US20100227317A1 (en) 2006-02-15 2007-02-15 Method for the Molecular Diagnosis of Prostate Cancer and Kit for Implementing Same
EP07730326A EP2000543A4 (en) 2006-02-15 2007-02-15 METHOD FOR THE MOLECULAR DIAGNOSIS OF PROSTATIC CANCER AND NECESSARY FOR CARRYING OUT SAID METHOD

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200600348A ES2300176B1 (es) 2006-02-15 2006-02-15 Metodo para el diagnostico molecular de cancer de prostata, kit para implementar el metodo.
ESP200600348 2006-02-15

Publications (2)

Publication Number Publication Date
WO2007093657A2 WO2007093657A2 (es) 2007-08-23
WO2007093657A3 true WO2007093657A3 (es) 2007-10-04

Family

ID=38371868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2007/000085 WO2007093657A2 (es) 2006-02-15 2007-02-15 Método para el diagnóstico molecular de cáncer de próstata y kit para implementar el método

Country Status (4)

Country Link
US (1) US20100227317A1 (es)
EP (1) EP2000543A4 (es)
ES (1) ES2300176B1 (es)
WO (1) WO2007093657A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
CN102301002A (zh) 2008-11-12 2011-12-28 卡里斯生命科学卢森堡控股有限责任公司 使用外来体来确定表现型的方法和系统
WO2010056993A2 (en) * 2008-11-14 2010-05-20 Emory University Prostate cancer biomarkers to predict recurrence and metastatic potential
FR2945820A1 (fr) * 2009-05-25 2010-11-26 Univ Clermont Auvergne Panel de genes pour le pronostic du cancer de la prostate
CA2790506A1 (en) * 2010-02-22 2011-08-25 Curna, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
JP2011206049A (ja) * 2010-03-08 2011-10-20 Sumio Sugano 壊死マーカー及びその用途
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
US20130202717A1 (en) * 2010-06-01 2013-08-08 Indiana University Research And Technology Corporation Materials and methods for diagnosing and predicting the course of prostate cancer
EP3556870B9 (en) * 2010-07-27 2022-09-28 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
EP2418491A1 (en) * 2010-08-10 2012-02-15 Bioftalmik, S.L. Method for the diagnosis of dry eye and blepharitis
EP2606130B1 (en) * 2010-08-16 2019-03-13 Duke University Camkk-beta as a marker in prostate cancer
CN102094084B (zh) * 2010-11-24 2012-09-19 中山大学附属第三医院 检测EphA2基因表达量的荧光定量PCR方法及试剂盒与应用
EP2683837A2 (en) 2011-03-07 2014-01-15 University Of Louisville Research Foundation, Inc. Predictive marker of dnmt1 inhibitor therapeutic efficacy and methods of using the marker
CA2835730C (en) * 2011-05-12 2021-06-01 Noviogendix Research B.V. Molecular markers in prostate cancer
ES2616129T3 (es) * 2011-11-04 2017-06-09 Mdxhealth Research B.V. Combinaciones de marcadores moleculares en cáncer de próstata que proporcionan una herramienta para diagnóstico con mejor sensibilidad/especificidad
MX351626B (es) 2012-01-31 2017-10-23 Genomic Health Inc Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
EP2861767A4 (en) * 2012-06-15 2016-07-27 Nuclea Biotechnologies Inc PREDICTIVE MARKERS FOR CANCER AND METAL CHANGE SYNDROME
EP2875157A4 (en) * 2012-07-20 2016-10-26 Diagnocure Inc METHOD, KITS AND COMPOSITIONS FOR THE CLINICAL EVALUATION OF PROSTATE CANCER
US20160195535A1 (en) * 2012-12-20 2016-07-07 National University Corporation Hokkaido University Method for detecting prostatic basal cells
EP3214444A1 (en) * 2016-03-04 2017-09-06 AIT Austrian Institute of Technology GmbH Prostate cancer diagnostic method and means
CN107312846A (zh) * 2017-07-12 2017-11-03 北京赛尔维康生物医学科技有限公司 Capg和ptgis基因在制备脊柱侧弯检测试剂盒中的应用
KR102229255B1 (ko) * 2018-12-28 2021-03-19 경북대학교 산학협력단 전립선 암 예후 예측용 바이오마커, 조성물, 키트, 및 이를 이용한 전립선 암 예후 예측 방법 및 전립선 암의 예방 또는 치료용 물질 스크리닝 방법
CN110031637A (zh) * 2019-05-24 2019-07-19 广州和盈医疗科技有限公司 一种用于强直性脊柱炎治疗跟踪与监测的试剂盒及其应用
EP4373860A1 (en) * 2021-07-21 2024-05-29 Mercy Bioanalytics, Inc. Compositions and methods for detection of prostate cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171796B1 (en) * 1998-01-21 2001-01-09 Urocor, Inc. Biomarkers and targets for diagnosis prognosis and management of prostate disease
WO2006091776A2 (en) * 2005-02-25 2006-08-31 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070092917A1 (en) * 1998-05-01 2007-04-26 Isabelle Guyon Biomarkers for screening, predicting, and monitoring prostate disease
AU2001280889A1 (en) * 2000-07-31 2002-02-13 Gene Logic, Inc. Molecular toxicology modeling
US8088358B2 (en) * 2001-03-08 2012-01-03 Centrum Fur Angewandte Nanotechnologie (Can) Gmbh Paramagnetic nanoparticle
US20080171318A1 (en) * 2004-09-30 2008-07-17 Epigenomics Ag Epigenetic Methods and Nucleic Acids for the Detection of Lung Cell Proliferative Disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171796B1 (en) * 1998-01-21 2001-01-09 Urocor, Inc. Biomarkers and targets for diagnosis prognosis and management of prostate disease
WO2006091776A2 (en) * 2005-02-25 2006-08-31 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BISMAR T.A. ET AL.: "Defining aggressive prostate cancer using a 12-gene model", NEOPLASIA, vol. 8, no. 1, 2006, pages 59 - 68, XP002507798 *
GLINSKY G.V. ET AL.: "Gene expression profiling predicts clinical outcome of prostate cancer", J. CLIN. INVEST., vol. 113, no. 6, 2004, pages 913 - 923, XP002395330 *
LAPOINTE J. ET AL.: "Gene expressing profiling identifies clinically relevant subtypes of prostate cancer", PROC. NATL. ACAD. SCI. U S A, vol. 101, no. 3, 2004, pages 811 - 816, XP002395334 *
OUDES A.J. ET AL.: "Application of Affymetrix array and Massively Parall the Signature Sequence for identification of genes involved in prostate cancer progression", BMC CANCER, vol. 5, 2005, pages 86, XP021004851 *
RHODES D.R. ET AL.: "Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression", PROC. NATL. ACAD. SCI. U S A, vol. 101, no. 25, 2004, pages 9309 - 9314, XP002365382 *
RHODES D.R. ET AL.: "Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer", CANCER RES., vol. 62, no. 15, 2002, pages 4427 - 4433, XP002266908 *
VARAMBALLY S. ET AL.: "Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression", CANCER RES., vol. 8, no. 5, 2005, pages 393 - 406, XP002395335 *

Also Published As

Publication number Publication date
WO2007093657A2 (es) 2007-08-23
EP2000543A4 (en) 2010-09-01
US20100227317A1 (en) 2010-09-09
EP2000543A2 (en) 2008-12-10
ES2300176B1 (es) 2009-05-01
ES2300176A1 (es) 2008-06-01

Similar Documents

Publication Publication Date Title
WO2007093657A3 (es) Método para el diagnóstico molecular de cáncer de próstata y kit para implementar el método
WO2009036427A3 (en) Prostate cancer biomarkers
EP1922326A4 (en) BIOMARKERS USEFUL FOR DIAGNOSING PROSTATE CANCER AND METHOD OF USE THEREOF
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2006012646A3 (en) Amacr cancer markers
WO2008061104A3 (en) Methods and kits for detecting prostate cancer biomarkers
WO2009012140A3 (en) Drug selection for lung cancer therapy using antibody-based arrays
WO2008011519A3 (en) Amigo-2 inhibitors for treating, diagnosing or detecting cancer
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2007134210A3 (en) Methods and compositions for the diagnosis and treatment of cancer
WO2010045318A3 (en) Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2007095644A3 (en) Reagents and methods for cancer prognosis and pathological staging
WO2010009337A3 (en) Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
WO2007039290A3 (en) Methods and nucleic acids for the analysis of gene expression associated with the prognosis of cell proliferative disorders
WO2008061213A3 (en) Genetic variations associated with tumors
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2008061020A3 (en) Methods of treating, diagnosing or detecting cancer
WO2008060363A8 (en) Tumor associated markers in the diagnosis of prostate cancer
WO2006034456A3 (en) Compositions and methods for detecting and treating tumors
WO2007033167A3 (en) Compositions and methods for detecting and treating cancer
WO2011074802A3 (ko) 전립선암 진단용 키트 및 진단방법
WO2009085196A8 (en) Methods and compositions for correlating genetic markers with prostate cancer risk
WO2008092002A3 (en) Compositions and methods for treating and diagnosing pancreatic cancer
WO2008070325A3 (en) Genetic variations associated with tumors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007730326

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12224061

Country of ref document: US